Aim: Ketorolac tromethamine (KT) is highly effective in treating post-operative eye inflammation, allergic conjunctivitis as well other ailments. It is reported that USFDA has approved a 0.45% ophthalmic solution of KT (Acuvail, Allergan, Inc) for the treatment of pain and inflammation after cataract surgery. However, the bioavailable amount of an ocular dosage form is very low due to continuous defensive mechanism in the eye. Thus the aim of present study was to improve the bioavailability of KT via sustained release using the polymer matrix (Chitosan) as a carrier. Materials and Methods: Nanoparticles of Ketorolac tromethamine were prepared by ionotropic gelation method. Design expert software was used to evaluate the effect of chitosan and tripolyphosphate (TPP) concentration on particle size and entrapment efficiency of nanoparticles. Prepared nanoparticles were physico-chemically characterized for % yield, entrapment efficiency, particle size and Zeta potential, surface morphology, in-vitro drug release, release kinetics and stability studies. In accordance with the evaluation parameters and results obtained from factorial design, an optimized batch was designed and evaluated for above mentioned parameters. Results: The optimized batch thus prepared was having Percentage yield (66.4%), Percentage Entrapment Efficiency (61.65%), Particle size (153.9 nm), Zeta Potential (-21.8) and percentage drug release (94.368±0.181 & 92.797±0.150% in PBS and STF (pH 7.4) respectively). Results of release kinetic study revealed that drug dissolution followed Zero order release kinetics model. No physicochemical changes were seen when stored at accelerated conditions. Conclusion: It was concluded that the principle adopted behind this research work will provide impetus for future researchers to carry out such formulations of wider variety of drugs rendering highly economical utility.
INTRODUCTION
Inflammation is the indication of cellular and vascular response of the host tissue to injury which may be inflicted by physical or chemical agents, invasion of pathogens, ischemia, and excessive (hypersensitivity) or inappropriate (autoimmunity) operation of immune mechanisms. Post-operative inflammation includes distracted aqueous-blood barrier, excessive blood flow in conjunctival vessels, miosis, elevated IOP, intervened by COX pathways.
1-2 Ocular inflammation most frequently hastens due to infection, allergens, surgical intervention or trauma.
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Various ocular problems/diseases i.e. intraoperative miosis (during cataract surgery), postoperative inflammation, cystoid macular edema (CME) following cataract extraction, seasonal allergic conjunctivitis, ocular dis-comfort (pain and photophobia) after refractive surgery, Diabetic retinopathy (DR) and Diabetic macular edema (DME) are prevented/treated by various drugs belonging to NSAID class. [1] [2] [3] [4] Eye-drops accounts for the 90% of currently accessible conventional ophthalmic formulations. The bioavailable amount of an ocular dosage form is very low due to continuous defensive mechanism in the eye. The instilled amount of drug is continuously wiped out from the retinal flora because of blinking and involuntary lachrymation. Also, the faster absorption of applied drugs is more massed by the anatomy, physiology and barrier functions of cornea.
5 Nanoparticles have been formulated as eye drops or injectables to surmount ocular obstacles faced after administration. Better drug pharmacodynamics and pharmacokinetics, immunogenicity, bio recognition and non-specific toxicity can be achieved to improve drug efficacy by loading drugs in the nanoparticles. [6] [7] [8] [9] Chitosan nanoparticles are good drug carriers because of their good biocompatibility and biodegradability, and can be readily modified. [10] [11] Ketorolac tromethamine (KT) belongs to pyrrolo-pyrrole group of NSAIDs. Its chemical name is (±)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid, compound with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1). It is highly effective in relieving pain after radial keratotomy (RK), photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK); acute pseudophakic cystoid macular edema (PCME) and to treat allergic conjunctivitis pertaining to inhibition of ocular PG synthesis. [12] [13] Hence, the present worker conceptualized "Chitosan loaded Ketorolac tromethamine nanoparticles for improved ocular delivery in Eye inflammation" that would fulminate into improved therapy. The outcomes of research work, in reference, would contribute to the society in getting rid of such problems by recognizing ultimate ease and least negligence to maintain the drug therapy i.e. least possible frequency of administration, higher ocular residence time and thus sustained longer duration of action.
MATERIALS AND METHOD

Materials
Ketorolac tromethamine was procured from Panchsheel Organics Ltd, Indore. Chitosan (Medium grade; 400 KD) was purchased from Evonik Industries, Mumbai, MHA. Other chemicals i.e. Glacial acetic acid, Span-80, Ethanol, Sodium hydroxide, Sodium chloride, Sodium bicarbonate, Calcium chloride dihydrate, Sodium tripolyphosphate, Potassium dihydrogen phosphate were procured from various companies.
Methods
FTIR and TLC study
Drug (Ketorolac tromethamine)-excipient compatibility was checked by adopting IR spectroscopy and densitometric TLC analyses. Infra-red spectra of pure drug alone and with chosen ingredients were recorded on FTIR (Shimadzu IR Affinity -1 ) spectroscopy at a resolution of 2 cm -1 ranged from 4000 to 400 cm -1 using KBr discs. Ketorolac tromethamine was analyzed densitometrically using combination of glacial acetic acid: acetone: dichloromethane (mobile phase) in ratio 1:1:9 % v/v, respectively. Obtained spots were detected at 322 nm.
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Preparation of Ketorolac tromethamine loaded Chitosan nanoparticles
Drug (Ketorolac tromethamine) laden nanoparticles were produced by ionotropic gelation method using chitosan and sodium tri-polyphosphate (Na-TPP). Prepared product (suspension) was centrifuged (Remi, Mumbai, India) for 15 min. at 12000 rpm. Sediment was freeze dried (Lyophilizer, Biogen-model no BGS214, India) for 48 h. The obtained nanoparticles were stored under dehydrated conditions for further studies ( Figure 1 ).
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Experimental design
Design Expert (Version 9.0, Stat-Ease Inc., Minneapolis, MN) was used for optimization study of ketorolac tromethamine nanoparticles consisted of 2 independent factors i.e. amount of chitosan (X1) and sodium tri-poly phosphate (X2) which were evaluated, at 3 levels (-1, 0, 1 i.e. 100, 200 and 300 respectively) and 9 experimental trials were performed with reference to particle size and percent (%) entrapment as dependent variables (Table 1) . All other processing variables were kept constant throughout the study. The average diameter and zeta potential of drug-loaded nanoparticles were measured by dynamic light scattering method using Zetasizer nano zs (Malvern instrument ltd., Worcestershire, UK). Surface morphology was used to determine the shapes and distribution of particles and measured by SEM (XL series Quanta FEI 200F).
In-vitro Drug release
Drug release from drug-loaded nanoparticles was carried out by suspending the prepared nanoparticles in PBS (phosphate buffer saline, pH 7.4) in a conical flask (100 ml) and shaked on magnetic stirrer (150 cycles/min) at 37°C. Withdrawn samples were centrifuged at 12000 rpm and analyzed using UV spectrophotometry at 322 nm.
Ocular Irritancy test
The prepared nanoparticles belonging to optimized batch were evaluated for in-vivo performance in Albino rabbits. They were manipulated suitably for experimental conditions. Eyes were marked as test and control respectively. The control eyes received no sample while the test eyes received the nanoparticles, and observed for the ocular irritancy. The protocol was approved by Institutional Animal Ethical Committee.
17 Accelerated (Physical) Stability studies ICH (International Conference of Harmonization) guidelines were followed to carry out the stability study of optimized formulation. The optimized formulation was stored at accelerated conditions (40 0 ±2 0 C/75%±5% RH) for six months respectively and reckoned, for released characteristics, at predetermined time period.
18
RESULTS AND DISCUSSION
FTIR analysis
The FTIR spectra of pure drug resulted in characteristic peaks which resembled with those obtained with the combinations. In the spectrum of ketorolac tromethamine (Figure 2A C-O-C and 1908 cm-1; NH 2 , were observed in spectra obtained with chitosan ( Figure 2B ). Hence, drug polymer compatibility was confirmed by confinement of distinctive peaks of pure drug in its combination with chitosan.
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Thin Layer Chromatography (TLC) Method
Nearly similar R f values of the drug alone and its combinations with selected polymer confirmed their compatibility. R f value of pure drug i.e. ketorolac 
Formulation, Optimization and Evaluation
In the present investigation, selected independent variables were amount of chitosan and TPP while the particle size and percentage drug entrapment was selected as dependent variables. The selected independent variables were studied at different levels to observe their individual as well as interactive effects. Particle size of prepared nanoparticles ranged between 155.5-200.4 nm and quadratic model was best suited for the data which was validated by ANOVA. As mentioned in Table 2 , the Model F-value is 710.34, which implies that model is significant. Moreover, the factor A had shown more effect on Particle size of nanoparticles with F-value of 3121.64 (p<0.0001) than factor B with F-value of 393.90 (p<0.05). The predicted R 2 of 0.9898 was significantly correlated with adjusted R 2 of 0.9977; i.e. the difference is less than 0.2. Signal to noise ratio greater than 4 is desirable, and in the present study, it is 75.719 that indicated an adequate signal. Polynomial equation thus generated was as shown below (equation 1):
As shown in Figure 4a , the particle size decreased significantly with increase in concentrations of both factors i.e. chitosan and TPP which was presented in the form of contour and 3D response surface plots. It is already reported that as the concentration of chitosan and TPP increased, particle size decreased accordingly. [21] [22] Second dependent factor was chosen as percent (%) drug entrapment. Entrapment efficiency of prepared batches (A1-B3) was found between 38.86%-61.91%. As shown in encapsulation efficiency and vice-versa (Figure 4b ). It may be due to fact that increased size of polymer can encapsulate more drug, but more surfactant also accelerate the encapsulation by increasing the binding contact between drug and polymer in emulsion stage. 23 Desirability function was used for optimization to obtain the levels of process parameters in which particle size was kept at minimum and entrapment efficiency at maximum. Based on the results obtained from predicted solution ( Figure 5) given by optimization study, a checkpoint batch (OKT) was prepared and considered as optimized batch for further studies.
Physicochemical evaluation of KT nanoparticles
Percentage yield and Drug entrapment efficiency
Percentage yield of prepared nanoparticles (batches yield (58.9%) was obtained with batch C. Nanoencapsulation of therapeutic agents increases their targeting ability, specificity and efficacy. Moreover, they protect the drug from earlier degradation; improve bioavailability and cellular uptake and controlled drug release. [24] [25] Percent (%) drug entrapment was found between 38.86%-61.91% with batches A1-C3.
Particle size analysis and Zeta potential
It is reported that particle size has profound effect on drug release. Smaller the nanoparticle size resulted in greater surface area which leads to quick drug delivery. 26 Mean particle size consisting of all batches were found in the range of 155.5-200.4 nm. Nanoparticles comprised of batch C3 had smallest (155.5 nm) particle size. Nanoparticles with zeta potentials of less than −30 mV or greater than +30 mV are considered strongly anionic and strongly cationic, respectively and they show greater colloidal stability. Since most biological cells have negative zeta potential; thus zeta potential of nanoparticulate systems must be slightly negative so that they do not stick non-specifically to cells but interact through a receptor mediated interaction. 27 The zeta potential of prepared nanoparticles (batch A1-C3) ranged between (-9.58) to (-18.5) mV. Percentage yield, entrapment efficiency and mean particle size data of prepared batches (A1-C3) has shown in Figure 6 .
Surface Morphology
The Scanning Electron Microscope (SEM) is most versatile instrument available for examination and analysis of morphology and chemical characterization of nanomaterials. It is an important tool for characterization of particle morphology and its distribution. Ketorolac From the polynomial equation, it was shown that when factors i.e. A and B increased, the drug entrapment into polymer was also increased. It is reported that a decrease in weight ratio of CS/TPP, decreases the encapsulation efficiency of nanoparticles pertaining to more compact solid-matrix structure that had led to the increasing amount of nanoparticles formation, resulting in the increased nanoencapsulation. 22 Moreover, the maximum polymer and surfactant (TPP) concentration give more found to be in 90.23-96.87% and 89.22-95.65% in pH 7.4 PBS and STF respectively (Figure 7 ).
Evaluation Parameters for Optimized batch (OKT)
The optimized batch thus prepared was having Percentage yield (66.4%), % Entrapment Efficiency (61.65%), Particle size (153.9 nm), Zeta Potential (-21.8) and percentage drug release (94.368±0.181 and 92.797±0.150% in PBS and STF (pH 7.4) respectively) (Figure 8, 9) . Results of release kinetic study revealed that drug dissolution followed Zero order release kinetics model ( Figure 10 ).
Ocular Irritancy test
No irritation was observed. tromethamine nanoparticles (batches A1-C3) were having rough surfaces with spherical in shape.
28
In-vitro release study
The release rate decreased with increase in cross-linking density. A dense matrix of the nanoparticles might exhibit slower release rate of the drug. 29 Percentage drug release from Ketorolac tromethamine nanoparticles was
